Filing Details

Accession Number:
0001209191-17-022569
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-03-23 16:26:15
Reporting Period:
2017-03-21
Filing Date:
2017-03-23
Accepted Time:
2017-03-23 16:26:15
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1505512 Regulus Therapeutics Inc. RGLS () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1202098 Stelios Papadopoulos C/O Regulus Therapeutics Inc.
10614 Science Center Drive
San Diego CA 92121
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-03-21 200,000 $1.20 400,677 No 4 P Direct
Common Stock Acquisiton 2017-03-22 300,000 $1.23 700,677 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.18775 to $1.20 inclusive. The reporting person undertakes to provide to RGLS, any security holder of RGLS, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.
  2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.175 to $1.25 inclusive. The reporting person undertakes to provide to RGLS, any security holder of RGLS, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.